Table 1 Baseline characteristics for patients in the total cohort, with early and established RA
Total cohort | Men | Women | All |
|---|---|---|---|
Number | 527 | 1401 | 1928 |
Age (years) mean (SD) | 60.5 (14.7) | 59.5 (15.9) | 59.8 (15.6) |
RA duration at inclusion (years), median (IQR) | 3 (0–14) | 3 (0–14) | 3 (0–14) |
RA duration at first questionnaire (years), median (IQR) | 7 (4–17) | 7 (4–17) | 7 (4–17) |
RF-positive n (%) | 322 (73.5) | 855 (73.3) | 1177 (73.3) |
HAQ mean (SD)* | 0.75 (0.68) | 1.1 (0.76) | 0.97 (0.75) |
VAS pain (mm) mean (SD)* | 37.9 (27.4) | 44.5 (26.5) | 42.7 (26.9) |
VAS global health (mm) mean (SD)* | 38.2 (26.4) | 42.7 (26.2) | 41.5 (26.3) |
Methotrexate n (%)* | 189 (46.1) | 479 (43.0) | 668 (43.9) |
csDMARDs other than Methotrexate n (%)* | 114 (27.8) | 321 (28.8) | 435 (28.6) |
bDMARDs n (%)* | 42 (10.2) | 121 (10.9) | 163 (10.7) |
Prednisolone n (%)* | 105 (25.6) | 273 (24.5) | 378 (24.8) |
Previous osteoporosis-related fracture n (%) | 13 (2.5) | 81 (5.8) | 94 (4.9) |
Early RA¶ | Men | Women | All |
Number | 211 | 527 | 738 |
Age (years) mean (SD) | 57.9 (14.7) | 55.4 (16.8) | 56.1 (16.3) |
RA duration at inclusion (years), median (IQR) | < 1 (< 1-<1) | < 1 (< 1-<1) | < 1 (< 1-<1) |
RA duration at first questionnaire (years), median (IQR) | 4 (2–5) | 4 (2–5) | 4 (2–5) |
RF-positive n (%) | 127 (67.7) | 303 (66.3) | 430 (66.7) |
HAQ mean (SD)* | 0.63 (0.59) | 0.77 (0.57) | 0.73 (0.58) |
VAS pain (mm) mean (SD)* | 37.3 (27.1) | 40.1 (24.9) | 39.4 (25.5) |
VAS global health (mm) mean (SD)* | 38.1 (26.6) | 39.1 (24.4) | 38.9 (25.0) |
Methotrexate n (%)* | 101 (67.3) | 256 (62.6) | 357 (63.9) |
csDMARDs other than Methotrexate n (%)* | 41 (27.3) | 105 (25.7) | 146 (26.1) |
bDMARDs n (%)* | 26 (17.3) | 72 (17.6) | 98 (17.5) |
Prednisolone n (%)* | 37 (24.7) | 94 (23.0) | 131 (23.4) |
Previous osteoporosis-related fracture n (%) | 1 (0.5) | 12 (2.3) | 13 (1.8) |
Established RA¶¶ | Men | Women | All |
Number | 237 | 638 | 875 |
Age (years) mean (SD) | 64.1 (13.3) | 63.4 (13.9) | 63.6 (13.7) |
RA duration at inclusion (years), median (IQR) | 14 (9–22) | 15 (9–26) | 15 (9–25) |
RA duration at first questionnaire (years), median (IQR) | 18 (11–25) | 18 (11–27) | 18 (11–27) |
RF-positive n (%) | 141 (79.2) | 402 (80.9) | 543 (80.4) |
HAQ mean (SD)* | 0.96 (0.74) | 1.35 (0.80) | 1.24 (0.80) |
VAS pain (mm) mean (SD)* | 41.1 (27.7) | 48.7 (27.2) | 46.6 (27.6) |
VAS global health (mm) mean (SD)* | 41.3 (27.0) | 46.5 (27.2) | 45.0 (27.2) |
Methotrexate n (%)* | 62 (32.3) | 157 (30.8) | 219 (31.2) |
csDMARDs other than Methotrexate n (%)* | 52 (27.1) | 149 (29.3) | 201 (28.7) |
bDMARDs n (%)* | 13 (6.8) | 38 (7.5) | 51 (7.3) |
Prednisolone n (%)* | 56 (29.2) | 130 (25.5) | 186 (26.5) |
Previous osteoporosis-related fracture n (%) | 10 (4.2) | 61 (9.6) | 71 (8.1) |